InMode (INMD) Competitors $15.05 +0.02 (+0.13%) Closing price 04:00 PM EasternExtended Trading$15.06 +0.01 (+0.10%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INMD vs. SLNO, NVST, WRBY, LIVN, EYE, INSP, PRCT, LQDA, AORT, and LMATShould you be buying InMode stock or one of its competitors? The main competitors of InMode include Soleno Therapeutics (SLNO), Envista (NVST), Warby Parker (WRBY), LivaNova (LIVN), National Vision (EYE), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), Liquidia Technologies (LQDA), Artivion (AORT), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry. InMode vs. Its Competitors Soleno Therapeutics Envista Warby Parker LivaNova National Vision Inspire Medical Systems PROCEPT BioRobotics Liquidia Technologies Artivion LeMaitre Vascular Soleno Therapeutics (NASDAQ:SLNO) and InMode (NASDAQ:INMD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Does the media refer more to SLNO or INMD? In the previous week, Soleno Therapeutics had 9 more articles in the media than InMode. MarketBeat recorded 10 mentions for Soleno Therapeutics and 1 mentions for InMode. InMode's average media sentiment score of 1.11 beat Soleno Therapeutics' score of 0.08 indicating that InMode is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InMode 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, SLNO or INMD? InMode has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$175.85M-$4.14-15.15InMode$394.82M2.41$181.27M$2.476.09 Do institutionals & insiders believe in SLNO or INMD? 97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 6.9% of InMode shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is SLNO or INMD more profitable? InMode has a net margin of 44.50% compared to Soleno Therapeutics' net margin of 0.00%. InMode's return on equity of 18.38% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -73.74% -56.67% InMode 44.50%18.38%16.35% Which has more risk and volatility, SLNO or INMD? Soleno Therapeutics has a beta of -2.75, meaning that its share price is 375% less volatile than the S&P 500. Comparatively, InMode has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500. Do analysts prefer SLNO or INMD? Soleno Therapeutics currently has a consensus price target of $115.92, indicating a potential upside of 84.76%. InMode has a consensus price target of $18.04, indicating a potential upside of 19.88%. Given Soleno Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Soleno Therapeutics is more favorable than InMode.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.93InMode 1 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryInMode beats Soleno Therapeutics on 10 of the 16 factors compared between the two stocks. Get InMode News Delivered to You Automatically Sign up to receive the latest news and ratings for INMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMD vs. The Competition Export to ExcelMetricInModeMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$950.03M$10.66B$6.11B$10.56BDividend YieldN/A1.87%5.69%4.75%P/E Ratio6.0921.8785.4827.60Price / Sales2.4125.41624.19239.62Price / Cash8.2425.4637.9261.55Price / Book1.493.4513.136.76Net Income$181.27M$208.83M$3.30B$275.88M7 Day Performance-1.51%2.10%5.29%3.72%1 Month Performance-1.51%2.77%9.94%10.22%1 Year Performance1.14%-5.21%87.78%35.86% InMode Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMDInMode3.1655 of 5 stars$15.05+0.1%$18.04+19.9%-0.5%$950.03M$394.82M6.09480Positive NewsAnalyst ForecastSLNOSoleno Therapeutics4.4004 of 5 stars$68.16+4.9%$115.09+68.9%+30.4%$3.62BN/A-16.4630Analyst ForecastNVSTEnvista3.769 of 5 stars$20.22-0.7%$20.92+3.5%+11.8%$3.36B$2.51B63.1712,300Analyst ForecastWRBYWarby Parker1.8567 of 5 stars$27.69+0.3%$24.06-13.1%+50.6%$2.91B$771.32M-395.513,780News CoveragePositive NewsAnalyst ForecastLIVNLivaNova2.3147 of 5 stars$52.33-2.1%$59.71+14.1%-1.0%$2.86B$1.25B-13.452,900Analyst ForecastEYENational Vision2.6095 of 5 stars$29.24+2.5%$24.73-15.4%+169.4%$2.32B$1.82B-162.4413,411Positive NewsAnalyst ForecastINSPInspire Medical Systems4.8182 of 5 stars$75.46-2.3%$154.43+104.6%-62.9%$2.23B$802.80M43.621,246Analyst ForecastPRCTPROCEPT BioRobotics2.9386 of 5 stars$36.49-0.5%$70.00+91.8%-50.3%$2.03B$224.50M-23.54430Analyst ForecastLQDALiquidia Technologies3.4296 of 5 stars$22.80+4.6%$32.11+40.8%+115.4%$1.96B$14M-13.4150News CoveragePositive NewsAnalyst ForecastGap UpAORTArtivion3.318 of 5 stars$42.03+2.4%$43.13+2.6%+57.4%$1.94B$388.54M97.761,600Analyst ForecastLMATLeMaitre Vascular3.8705 of 5 stars$85.45+1.5%$97.60+14.2%-3.0%$1.93B$219.86M41.48490Analyst Forecast Related Companies and Tools Related Companies SLNO Alternatives NVST Alternatives WRBY Alternatives LIVN Alternatives EYE Alternatives INSP Alternatives PRCT Alternatives LQDA Alternatives AORT Alternatives LMAT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INMD) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredHow to profit from the AI maniaPorter Stansberry says the AI boom’s next trillion-dollar winners won’t be chatbots or Big Tech — but the over...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMode Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMode With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
